The structure-activity relationships for a series of pyrazine-based A2B adenosine receptor antagonists are described. From this work, LAS101057 (17), a potent, selective, and orally efficacious A2B receptor antagonist, was identified as a clinical development candidate. LAS101057 inhibits agonist-induced IL-6 production in human fibroblasts and is active in an ovalbumin (OVA)-sensitized mouse model after oral administration, reducing airway hyperresponsiveness to methacholine, Th2 cytokine production, and OVA-specific IgE levels.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018059 | PMC |
| http://dx.doi.org/10.1021/ml100249e | DOI Listing |
Publication Analysis
Top Keywords
las101057 potent
8
potent selective
8
selective orally
8
orally efficacious
8
efficacious a2b
8
a2b adenosine
8
adenosine receptor
8
receptor antagonist
8
discovery las101057
4
antagonist structure-activity
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!